Considering that GH secretion is most commonly impaired in HPs, GH replacement therapy has been demonstrated to improve elevated levels of liver enzyme, reduce hepatic steatosis and histological changes, while also leading to a decrease in fibrotic markers (10, 11). The gene discussed is GH1; the disease is Hepatic steatosis.